Vinorelbine and Cisplatin for Metastatic Breast Cancer: A Salvage Regimen in Patients Progressing After Docetaxel and Anthracycline Treatment

References

• Henderson I.C., Canellos G.P. Cancer of the breast, the past decade (part I). N. Engl. J. Med. 1980; 302: 17–30
   PubMed Web of Science ®Google Scholar
• Henderson I.C., Canellos G.P. Cancer of the breast, the past decade (part II). N. Engl. J. Med. 1980; 302: 78–90
   PubMed Web of Science ®Google Scholar
• A prospective randomized phase III trial combination chemotherapy with cyclophosphamide, fluoracil and either doxorubicin or epirubicin. J. Clin. Oncol. 1988; 6: 679–688
   PubMed Web of Science ®Google Scholar
• Bonadonna G., Gianni L., Santoro A., et al. Drugs ten years later: epirubicin (review). Ann. Oncol. 1993; 4: 359–369
   PubMed Web of Science ®Google Scholar
• Ten Bokkel Huinink W.W., Prove A.M., Piccart M., et al. A phase II trial with docetaxel (taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC-ECTG. Ann. Oncol. 1994; 5: 527–532
   PubMed Web of Science ®Google Scholar
• Hudis C.A., Seidman A.D., Crown J.P.A., et al. Phase II pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol. 1996; 14: 58–65
   PubMed Web of Science ®Google Scholar
• Fumoleau P., Chevallie B., Kerbrat P., et al. A multicenter phase II study of the efficacy and safety of docetaxel as first line treatment of advanced breast cancer: a report of the clinical screening group of the EORTC. Ann. Oncol. 1996; 7: 165–171
   PubMed Web of Science ®Google Scholar
• Alexopoulos C.G., Rigatos G., Efremidis A., et al. A phase II study of docetaxel (taxotere) in women with advanced breast cancer previously treated with polychemotherapy. Cancer Chemother. Pharmacol. 1999; 44: 253–258
   PubMed Web of Science ®Google Scholar
• Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 1999; 17(8)2341–2354
   PubMed Web of Science ®Google Scholar
• Dieras V. Docetaxel in combination with doxorubicin: a phase I dose-finding study. Oncology 1997; 6(Suppl. 6)17–20
   Google Scholar
• Dieras V., Barthier S., Beuzeboc P., et al. Phase II study of docetaxel in combination with doxorubicin as 1st line chemotherapy of metastatic breast cancer (abstract). Breast Cancer Res. Treat. 1998; 50: 262
   Google Scholar
• Nabholtz J.M., Smylie M., Noel D., et al. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer. Oncology 1997; 11(Suppl. 8)37–41
   PubMedGoogle Scholar
• Sparano J.A., Ju P., Schadfer P.L., et al. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group trial (E1196) (abstract). Breast Cancer Res. Treat. 1998; 50: 27
   PubMedGoogle Scholar
• Nabholtz J.M., Falkson G., Campos D., et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC (abstract 485). Proc. Am. Soc. Clin. Oncol. 1999; 18: 127a
   Google Scholar
• Henderson I.C., Berry D., Demetri G., et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC) (abstract). Proc. Am. Soc. Clin. Oncol. 1998; 17: 390a
   Google Scholar
• Miller K.D., McCaskill-Stevens W., Sisk J., et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J. Clin. Oncol. 1999; 17(10)3033–3037
   PubMed Web of Science ®Google Scholar
• von Minckwitz G., Costa S.D., Eiermann W., et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J. Clin. Oncol. 1999; 17(7)1999–2005
   PubMed Web of Science ®Google Scholar
• Fumoleau P., Delgado F.M., Delozier T., et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J. Clin. Oncol. 1993; 11: 1245–1252
   PubMed Web of Science ®Google Scholar
• Garcia-Conte J., Lluch A., Martin M., et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. J. Clin. Oncol. 1994; 5: 854–857
   Google Scholar
• Weber B.L., Vogel C.I., Jones S., et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J. Clin. Oncol. 1995; 13: 2722–2730
   PubMed Web of Science ®Google Scholar
• Sledge C.W., Loehrer P.J., Bruce J., et al. Cisplatin as first-line therapy for metastatic breast cancer. J. Clin. Oncol. 1988; 6(12)1811–1814
   PubMed Web of Science ®Google Scholar
• Kolaric K., Roth A. Phase II clinical trial of cis-dichlorodiammine platinum (Cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother. Pharmacol. 1983; 11: 108–112
   PubMed Web of Science ®Google Scholar
• Cros S., Wright M., Morimoto M., et al. Experimental activity of navelbine. Semin. Oncol. 1989; 16: 15–20
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I., Biron P., Bachelot T., et al. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer 1998; 82(1)134–140
   PubMed Web of Science ®Google Scholar
• Vassilomanolakis M., Koumakis G., Barbounis V., Demiri M., Pateras H., Efremidis A.P. Vinorelbine and cisplatin in metastatic breast cancer patients refractory or resistant to anthracyclines containing regimens. Ann. Oncol. 2000; 11: 1155–1160
   PubMed Web of Science ®Google Scholar
• Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Rittenberg C.N., Gralla R.J., Rehmeyer T.A., et al. Assessing and managing venous irritation associated with vinorelbine tartrate (navelbine). Oncol. Nurs. Forum 1995; 22(4)707–710
   PubMedGoogle Scholar
• Henderson I.C., Harris J.R., Kinne D.W., Hellman S. Cancer of breast. Cancer: Principles and Practice of Oncology, V.T. De Vita, S. Hellman, S.A. Rosenberg. 4th Ed., Lippincot, Philidelphia 1989; 1197–1268
   Google Scholar
• Porkka K., Blomavist C., Rissanen P., et al. Salvage therapies in women who fail to respond to first-line treatment with fluoracil, epirubicin and cyclophosphamide for advanced breast cancer. Clin. Oncol. 1994; 12: 1639–1647
   Web of Science ®Google Scholar
• Abrams J.S., Vena D.A., Baltz J., et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J. Clin. Oncol. 1995; 13: 2056–2065
   PubMed Web of Science ®Google Scholar
• Wilson W.H., Berg S., Bryant G., et al. Paclitaxel in doxorubicin-refractory or mitomycin-refractory breast cancer: a phase I/II trial with 96-hour infusion. J. Clin. Oncol. 1994; 12: 1621–1629
   PubMed Web of Science ®Google Scholar
• Nabholtz J.-M., Senn H.J., Bezwoda W.R., et al. Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J. Clin. Oncol. 1999; 17(5)1413–1424
   PubMed Web of Science ®Google Scholar
• Sjostrom J., Mouridsen H., Pluzanska A., et al. Taxotere versus methotrexate 5-fluorouracil in patients with metastatic breast cancer as 2nd line chemotherapy: a phase III study (abstract). Proc. Am. Soc. Clin. Oncol. 1998; 17: 111a
   Google Scholar
• Bonneterre J., Monnier A., Roche H., et al. Taxotere versus 5-fluorouracil+navelbine in patients with metastatic breast cancer as 2nd line chemotherapy: a phase III study (abstract). Proc. Am. Soc. Clin. Oncol. 1998; 17: 111a
   Google Scholar